JP2022507609A5 - - Google Patents
Info
- Publication number
- JP2022507609A5 JP2022507609A5 JP2021526727A JP2021526727A JP2022507609A5 JP 2022507609 A5 JP2022507609 A5 JP 2022507609A5 JP 2021526727 A JP2021526727 A JP 2021526727A JP 2021526727 A JP2021526727 A JP 2021526727A JP 2022507609 A5 JP2022507609 A5 JP 2022507609A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- expression
- subject
- day
- measured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024135447A JP2024167242A (ja) | 2018-11-16 | 2024-08-14 | 誘導された制御性Ｔ（ｉＴＲＥＧ）細胞を使用したＡＬＳ治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862768176P | 2018-11-16 | 2018-11-16 | |
| US62/768,176 | 2018-11-16 | ||
| US201962927075P | 2019-10-28 | 2019-10-28 | |
| US62/927,075 | 2019-10-28 | ||
| PCT/US2019/061818 WO2020102731A1 (en) | 2018-11-16 | 2019-11-15 | ALS TREATMENT USING INDUCED REGULATORY T (iTREG) CELLS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135447A Division JP2024167242A (ja) | 2018-11-16 | 2024-08-14 | 誘導された制御性Ｔ（ｉＴＲＥＧ）細胞を使用したＡＬＳ治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507609A JP2022507609A (ja) | 2022-01-18 |
| JP2022507609A5 true JP2022507609A5 (enExample) | 2022-11-24 |
| JP7539881B2 JP7539881B2 (ja) | 2024-08-26 |
Family
ID=70730603
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526727A Active JP7539881B2 (ja) | 2018-11-16 | 2019-11-15 | 誘導された制御性Ｔ（ｉＴＲＥＧ）細胞を使用したＡＬＳ治療 |
| JP2024135447A Pending JP2024167242A (ja) | 2018-11-16 | 2024-08-14 | 誘導された制御性Ｔ（ｉＴＲＥＧ）細胞を使用したＡＬＳ治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135447A Pending JP2024167242A (ja) | 2018-11-16 | 2024-08-14 | 誘導された制御性Ｔ（ｉＴＲＥＧ）細胞を使用したＡＬＳ治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12239647B2 (enExample) |
| EP (1) | EP3880306A4 (enExample) |
| JP (2) | JP7539881B2 (enExample) |
| KR (1) | KR20210102264A (enExample) |
| CN (2) | CN113573778B (enExample) |
| AU (1) | AU2019379604B2 (enExample) |
| CA (1) | CA3119599A1 (enExample) |
| WO (1) | WO2020102731A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021231806A1 (en) * | 2020-05-13 | 2021-11-18 | Rapa Therapeutics, Llc | Antigen presenting t cells, sensitized, manufactured t cells and methods of treatment using the same |
| EP4150060A4 (en) * | 2020-05-13 | 2024-06-19 | Rapa Therapeutics, LLC | TREATMENT OR PREVENTION OF PRO-INFLAMMATORY DISEASES OR CONDITIONS USING INDUCED REGULATORY T CELLS (IT) |
| EP4600352A1 (en) * | 2022-09-26 | 2025-08-13 | Kyoto University | T cell production method |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7718196B2 (en) | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
| US20040175827A1 (en) | 2001-07-02 | 2004-09-09 | Fowler Daniel H. | Methods of generating human cd4+ th2 cells and uses thereof |
| WO2003020904A2 (en) | 2001-08-31 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of generating human cd4+ th1 cells |
| CN101014699B (zh) | 2004-08-24 | 2010-05-26 | 富士软件株式会社 | 去分化型软骨细胞向软骨细胞的再分化用培养基 |
| AU2006274455B2 (en) * | 2005-07-27 | 2011-06-09 | Emil Toma | Zalcitabine (DDC) boosted lamivudine (3TC) compositions for antiretroviral therapy |
| JP5813321B2 (ja) | 2007-03-23 | 2015-11-17 | ウィスコンシン アラムニ リサーチ ファンデーション | 体細胞の再プログラム化 |
| DE102007039429A1 (de) * | 2007-08-21 | 2009-02-26 | Imtm Gmbh | Verfahren zur Aktivierung regulatorischer T-Zellen |
| US9057054B2 (en) | 2009-06-25 | 2015-06-16 | The Regents Of The University Of Michigan | Antigen-specific long-term memory T-cells |
| US9018006B2 (en) | 2010-07-23 | 2015-04-28 | The University Of Toledo | Stable Tregs and related materials and methods |
| WO2012110200A1 (en) | 2011-02-18 | 2012-08-23 | Merck Patent Gmbh | Cyclic peptide cyclo (l -arginyl - glycyl - l -aspartyl - d - phenylalanyl - n-methyl - l -valyl), compositions thereof, and use thereof in methods for treating graft -versus - host disease |
| US20130344081A1 (en) | 2011-03-07 | 2013-12-26 | The University Of Tokushima | Method of treating amyotrophic lateral sclerosis |
| CN103561722A (zh) * | 2011-04-13 | 2014-02-05 | 利发利希奥公司 | 用于抑制和／或调整炎性神经变性疾病中涉及到的效应t细胞的组合物和方法 |
| FR2974369B1 (fr) | 2011-04-20 | 2014-10-31 | Genzyme Polyclonals S A S | Amplification de cellules t regulatrices a l'aide d'immunoglobulines anti-thymocytes |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| EP3696262A1 (en) | 2011-11-23 | 2020-08-19 | The Trustees Of The University Of Pennsylvania | Use of pdl1 expressing cells to convert t cells into regulatory t cells |
| JP6164746B2 (ja) | 2012-05-22 | 2017-07-19 | 国立大学法人 東京大学 | 抗原特異的ｔ細胞の製造方法 |
| CA2908042C (en) | 2013-03-27 | 2023-01-31 | Immunovaccine Technologies Inc. | Method for improving the efficacy of a survivin vaccine in the treatment of cancer |
| US9326983B2 (en) | 2013-08-01 | 2016-05-03 | University Of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
| AU2015301509B2 (en) | 2014-08-14 | 2018-04-12 | Boehringer Ingelheim Animal Health USA Inc. | Novel cryopreservation bags and method of use thereof for closed system, high capacity cell-banking |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| US10808230B2 (en) | 2015-02-24 | 2020-10-20 | Board Of Regents, The University Of Texas System | Selection methods for genetically-modified T cells |
| WO2016196471A1 (en) | 2015-06-02 | 2016-12-08 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
| US10835593B2 (en) | 2015-08-27 | 2020-11-17 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Modified anthrax toxin protective antigen |
| EP3355924A1 (en) | 2015-09-29 | 2018-08-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Methods of treating and preventing amyotrophic lateral sclerosis |
| WO2017100403A1 (en) | 2015-12-08 | 2017-06-15 | Regents Of The University Of Minnesota | Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using |
| RU2018127657A (ru) * | 2015-12-30 | 2020-01-31 | Новартис Аг | Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью |
| WO2018024894A1 (en) * | 2016-08-05 | 2018-02-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ex vivo generation of mhcii restricted cd4+foxp3+ regulatory t cells and therapeutic uses thereof |
| US12324836B2 (en) | 2016-12-07 | 2025-06-10 | Transtarget, Inc. | Methods and compositions for vaccinating and boosting cancer patients |
| US20200405881A1 (en) | 2017-03-06 | 2020-12-31 | University Of Washington | Cell based methods and compositions for therapeutic agent delivery and treatments using same |
| CN109957544B (zh) | 2017-12-22 | 2023-09-12 | 财团法人工业技术研究院 | 体外活化及/或扩增免疫细胞的方法 |
-
2019
- 2019-11-15 AU AU2019379604A patent/AU2019379604B2/en active Active
- 2019-11-15 EP EP19884703.0A patent/EP3880306A4/en active Pending
- 2019-11-15 CN CN201980089240.4A patent/CN113573778B/zh active Active
- 2019-11-15 CN CN202510548982.6A patent/CN120555349A/zh active Pending
- 2019-11-15 CA CA3119599A patent/CA3119599A1/en active Pending
- 2019-11-15 JP JP2021526727A patent/JP7539881B2/ja active Active
- 2019-11-15 WO PCT/US2019/061818 patent/WO2020102731A1/en not_active Ceased
- 2019-11-15 KR KR1020217018488A patent/KR20210102264A/ko active Pending
-
2021
- 2021-05-14 US US17/320,891 patent/US12239647B2/en active Active
-
2024
- 2024-08-14 JP JP2024135447A patent/JP2024167242A/ja active Pending
- 2024-10-11 US US18/913,444 patent/US20250114358A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Optimization of metabolism to improve efficacy during CAR-T cell manufacturing | |
| Ehrenstein et al. | Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy | |
| Nadkarni et al. | Anti–TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β | |
| Lang et al. | Vitamin D status and the host resistance to infections: what it is currently (not) understood | |
| JP2020515257A5 (enExample) | ||
| JP2022507609A5 (enExample) | ||
| CN115369086A (zh) | 一种nk细胞扩大培养的培养方案 | |
| JP2016504039A5 (enExample) | ||
| Szanto et al. | Intracytoplasmic cytokine expression and T cell subset distribution in the peripheral blood of patients with ankylosing spondylitis | |
| Miyazaki et al. | Expansion of CD4+ CD28− T cells producing high levels of interferon-γ in peripheral blood of patients with multiple sclerosis | |
| Nikiforow et al. | Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease | |
| van Hooij et al. | BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease | |
| JP2024167242A (ja) | 誘導された制御性Ｔ（ｉＴＲＥＧ）細胞を使用したＡＬＳ治療 | |
| Lonial et al. | A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products | |
| JP2024516619A5 (enExample) | ||
| JP7119076B2 (ja) | Ｎｋ細胞培養用組成物、及びそれを利用してｎｋ細胞を培養する方法 | |
| EP3055419A2 (en) | Analyzing immune signaling networks for identification of therapeutic targets in complex chronic medical disorders, identification of a natural killer cell population as a potential therapeutic target for gulf war illness&myalgic encephalomyelitis/chronic fatigue syndrome, and modulation of natural killer cell function by stimulation with interleukin 15 | |
| Reyes et al. | Treatment with AM3 restores defective T-cell function in COPD patients | |
| CN103966117B (zh) | 乳酸戊糖片球菌及其用途 | |
| CN116574679A (zh) | 特异性nk细胞的制备方法及其应用 | |
| CA2330217C (en) | Therapeutic agent for a cancer and method of screening the same and health-care auxiliary food | |
| CN101874108A (zh) | 治疗肠炎性病症的组合物 | |
| WO2003039567A1 (fr) | Compositions anticancereuses | |
| TW201914596A (zh) | 腸道益生菌用於製備抑制大腸直腸癌細胞遷移的醫藥組合物的用途 | |
| EP3752598B1 (en) | Allogeneic composition |